UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Analgesic efficacy and tolerability of flupirtine vs. tramadol in patients with subacute low back pain: a double-blind multicentre trial

Current medical research and opinion, 2008-12, Vol.24 (12), p.3523-3530

2008

Volltextzugriff (PDF)

Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: A new type of drug/drug interaction

Clinical pharmacology and therapeutics, 2000-10, Vol.68 (4), p.345-355

2000

Volltextzugriff (PDF)

In vivo probes of drug transport: commonly used probe drugs to assess function of intestinal P-glycoprotein (ABCB1) in humans

Handbook of experimental pharmacology, 2011-01 (201), p.403

2011

Volltextzugriff (PDF)

S216 EFFICACY AND TOLERABILITY OF FLUPIRTINE IN MUSCULOSKELETAL PAIN – RESULTS OF A POOLED RE-ANALYSIS OF RANDOMIZED, DOUBLE-BLIND, CONTROLLED TRIALS

European journal of pain supplements, 2011-09, Vol.5 (1), p.227-227

2011

Volltextzugriff (PDF)

P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound

International journal of clinical pharmacology and therapeutics, 1998-01, Vol.36 (1), p.16

1998

Volltextzugriff (PDF)

Bioavailability of a new effervescent tablet of diclofenac

International journal of clinical pharmacology and therapeutics, 2000-11, Vol.38 (11), p.546-551

2000

Volltextzugriff (PDF)

Anti-anginal and anti-ischemic effects of the selective beta-blocker talinolol in patients with stable angina pectoris

International journal of clinical pharmacology and therapeutics, 2005-02, Vol.43 (2), p.63

2005

Volltextzugriff (PDF)

Oral bioavailability of digoxin is enhanced by talinolol: Evidence for involvement of intestinal P-glycoprotein

Clinical pharmacology and therapeutics, 2000-07, Vol.68 (1), p.6-12

2000

Volltextzugriff (PDF)

Unexpected effect of concomitantly administered curcumin on the pharmacokinetics of talinolol in healthy Chinese volunteers

European journal of clinical pharmacology, 2007-07, Vol.63 (7), p.663-668

2007

Volltextzugriff (PDF)

Simvastatin does not influence the intestinal P‐glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms

British journal of clinical pharmacology, 2006-04, Vol.61 (4), p.440-450

2006

Volltextzugriff (PDF)

Pharmacokinetics of oral talinolol following a single dose and during steady state in patients with chronic renal failure and healthy volunteers

International journal of clinical pharmacology and therapeutics, 2001-02, Vol.39 (2), p.61-66

2001

Volltextzugriff (PDF)

Direct demonstration of small intestinal secretion and site-dependent absorption of the β-blocker talinolol in humans

Clinical pharmacology and therapeutics, 1996-05, Vol.59 (5), p.541-549

1996

Volltextzugriff (PDF)

Effect of levothyroxine administration on intestinal P-glycoprotein expression: Consequences for drug disposition

Clinical pharmacology and therapeutics, 2002-09, Vol.72 (3), p.256-264

2002

Volltextzugriff (PDF)

Rifampin impairs steady-state bioavailability of talinolol: Potential role of P-gp

Clinical pharmacology and therapeutics, 1999-02, Vol.65 (2), p.180-180

1999

Volltextzugriff (PDF)

Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers : Concentration- and dose-dependent absorption in vitro and in vivo

Pharmaceutical research, 1996-04, Vol.13 (4), p.514-522

1996

Volltextzugriff (PDF)

Interaction of talinolol and sulfasalazine in the human gastrointestinal tract

European journal of clinical pharmacology, 1992-04, Vol.42 (4), p.461-462

1992

Volltextzugriff (PDF)

Dose-Effect and Kinetic-Dynamic Relationships of the (β-Adrenoceptor Blocking Properties of Various Doses of Talinolol in Healthy Humans

Journal of cardiovascular pharmacology, 1995-12, Vol.26 (6), p.879-888

1995

Volltextzugriff (PDF)

A single and multiple dose bioavailability study with carbamazepine 400 mg retard tablets with reference to enzyme autoinduction and circadian time differences

International journal of clinical pharmacology and therapeutics, 1997-11, Vol.35 (11), p.496

1997

Volltextzugriff (PDF)

Day-Night Variations in the Renal Excretion of the Antiarrhythmic Agent Tiracizine and Its Metabolites

Chronobiology international, 1995, Vol.12 (2), p.135-140

1995

Volltextzugriff (PDF)

Stereoselective disposition of talinolol in man

Journal of pharmaceutical sciences, 2002-02, Vol.91 (2), p.303-311

2002

Volltextzugriff (PDF)

Zur Beziehung von in-vitro- und in-vivo-Untersuchungen beim Menschen am Beispiel von Diclofenac-Suppositorien

Pharmazie, 1985, Vol.40 (11), p.784-786

1985

Volltextzugriff (PDF)

The influence of food on the absorption of diclofenac as a pure substance

International journal of clinical pharmacology, therapy, and toxicology, 1991-10, Vol.29 (10), p.418

1991

Volltextzugriff (PDF)

Biliary elimination of indomethacin in man

European journal of clinical pharmacology, 1986-01, Vol.29 (6), p.691-695

1986

Volltextzugriff (PDF)

Pharmacokinetics of the antiarrhythmic agent tiracizine: Steady state kinetics in comparison with single-dose kinetics

Biopharmaceutics & drug disposition, 1995-07, Vol.16 (5), p.427-441

1995

Volltextzugriff (PDF)

The biliary and renal elimination of the new muscarinic-1-antagonist AWD 26-06 in volunteers with T-tube after cholecystectomy

International journal of clinical pharmacology, therapy, and toxicology, 1992-11, Vol.30 (11), p.508

1992

Volltextzugriff (PDF)

1 – 25 von 73

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(44)
Mit Volltextzugriff
(34)

Publikationsform

Artikel
(72)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(58)
Adult
(43)
Male
(41)
Science & Technology
(36)
Life Sciences & Biomedicine
(35)
Pharmacology & Pharmacy
(29)
Female
(24)
Biological And Medical Sciences
(23)
Medical Sciences
(22)
Pharmacology. Drug Treatments
(22)
Biological Availability
(17)
Administration, Oral
(15)
Middle Aged
(15)
Kinetics
(14)
Propanolamines - Pharmacokinetics
(14)
Adrenergic Beta-Antagonists - Pharmacokinetics
(12)
Cardiovascular System
(12)
Half-Life
(12)
Dose-Response Relationship, Drug
(10)
Propanolamines - Administration & Dosage
(10)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Analgesic efficacy and tolerability of flupirtine vs. tramadol in patients with subacute low back pain: a double-blind multicentre trial

Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: A new type of drug/drug interaction

In vivo probes of drug transport: commonly used probe drugs to assess function of intestinal P-glycoprotein (ABCB1) in humans

S216 EFFICACY AND TOLERABILITY OF FLUPIRTINE IN MUSCULOSKELETAL PAIN – RESULTS OF A POOLED RE-ANALYSIS OF RANDOMIZED, DOUBLE-BLIND, CONTROLLED TRIALS

P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound

Bioavailability of a new effervescent tablet of diclofenac

Anti-anginal and anti-ischemic effects of the selective beta-blocker talinolol in patients with stable angina pectoris

Oral bioavailability of digoxin is enhanced by talinolol: Evidence for involvement of intestinal P-glycoprotein

Unexpected effect of concomitantly administered curcumin on the pharmacokinetics of talinolol in healthy Chinese volunteers

Simvastatin does not influence the intestinal P‐glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms

Pharmacokinetics of oral talinolol following a single dose and during steady state in patients with chronic renal failure and healthy volunteers

Direct demonstration of small intestinal secretion and site-dependent absorption of the β-blocker talinolol in humans

Effect of levothyroxine administration on intestinal P-glycoprotein expression: Consequences for drug disposition

Rifampin impairs steady-state bioavailability of talinolol: Potential role of P-gp

Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers : Concentration- and dose-dependent absorption in vitro and in vivo

Interaction of talinolol and sulfasalazine in the human gastrointestinal tract

Dose-Effect and Kinetic-Dynamic Relationships of the (β-Adrenoceptor Blocking Properties of Various Doses of Talinolol in Healthy Humans

A single and multiple dose bioavailability study with carbamazepine 400 mg retard tablets with reference to enzyme autoinduction and circadian time differences

Day-Night Variations in the Renal Excretion of the Antiarrhythmic Agent Tiracizine and Its Metabolites

Stereoselective disposition of talinolol in man

Zur Beziehung von in-vitro- und in-vivo-Untersuchungen beim Menschen am Beispiel von Diclofenac-Suppositorien

The influence of food on the absorption of diclofenac as a pure substance

Biliary elimination of indomethacin in man

Pharmacokinetics of the antiarrhythmic agent tiracizine: Steady state kinetics in comparison with single-dose kinetics

The biliary and renal elimination of the new muscarinic-1-antagonist AWD 26-06 in volunteers with T-tube after cholecystectomy

Suchergebnisse filtern